• Kintara offers peek at mid-stage data in relapsed glioblastoma patients; Jazz wins quick approval for pediatric cancer drug

    3 monthes ago - By San Diego Biotechnology

    Among the dozens of cancer types, glioblastoma has proven one of the hardest to crack with little clinical success over the years. Now, a San Diego biotech is rolling out mid-stage data it claims could be pointing its drug in the right direction in relapsed patients. But there are several...
    Read more ...

     

  • Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

    3 monthes ago - By San Diego Biotechnology

    SAN DIEGO: SAN DIEGO, July 1, 2021 /PRNewswire/ - Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced ZYNRELEF extended-release solution, is now commercially...
    Read more ...

     

  • Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

    3 monthes ago - By San Diego Biotechnology

    SAN DIEGO: SAN DIEGO, July 1, 2021 /PRNewswire/ - Kintara Therapeutics, Inc. , a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, today announced topline data results from the recurrent arm of its open-label, Phase...
    Read more ...